A guide to separating a grade claim, an analytical result and a manufacturing-quality system.
A label can say “pharmaceutical grade,” a certificate can report 99% purity, and a product description can mention USP. Those statements may sound like three ways of saying the same thing. They answer different questions. A useful purchasing decision starts by asking what each statement covers, what evidence supports it, and whether that evidence fits the intended laboratory use.
The mistake is treating a familiar quality word as a substitute for the specification. A specification identifies the material, the attributes being controlled, the acceptance limits and the methods used to judge them. A broad label without those details leaves important questions open. This article explains how to make those questions concrete; it does not certify any particular supplier or batch.
Start with the claim's object
Ask whether the claim applies to a starting ingredient, a supplied bulk material, a finished formulation or the manufacturing facility. Evidence about one object does not automatically describe another. A manufacturer's quality system and a laboratory result also have different roles: one concerns how quality is built and maintained, while the other reports the result of a defined examination.
FDA describes current good manufacturing practice, or CGMP, as systems for designing, monitoring and controlling manufacturing processes and facilities. Its explanation emphasizes that quality must be built into production; testing a small portion of a batch at the end cannot by itself establish all aspects of product quality.[1] Consequently, a purity certificate should not be read as evidence that every manufacturing control has been assessed.
For a laboratory purchase, translate an adjective into a request: “Please provide the specification and batch-specific results supporting this claim.” That request is more informative than asking whether the material is simply “high grade.” It gives the supplier an opportunity to explain exactly what was controlled.
| Label statement | What to request | What stays separate |
|---|---|---|
| USP claim | Exact monograph and basis | Product approval |
| 99% purity | Method and calculation | Total vial composition |
| CGMP claim | Scope and supporting records | A particular assay result |
| Research use | Intended-use specification | Clinical suitability |
Read USP as a standards reference
USP-NF is a compendium of standards, including individual drug-substance and drug-product monographs. FDA's July 2019 draft guidance on its pending-monograph process describes compendial standards and drug-application review as related but distinct processes. It identifies USP as a private, nongovernmental organization.[4] That historical draft is background here, not a statement of a newly adopted requirement.
A practical follow-up to “USP grade” is therefore: Which material and monograph, which official version, and what batch evidence demonstrates conformity with the applicable requirements? A reference to one test should not be expanded into a claim that every applicable standard was assessed. Likewise, a standards reference should not be presented as a substitute for a product's regulatory status.
When a supplier cannot identify the basis of its wording, record the claim as unresolved rather than supplying a favorable interpretation yourself. If the material is an intermediate, mixture or particular salt form, establish that the cited standard actually describes that object. Similar names can hide a mismatch between what was purchased and what was tested.
Ask what the purity percentage measures
A percentage needs a numerator, denominator and measurement procedure. For chromatographic area purity, the calculation concerns the signals included under the stated method. It is not automatically a mass fraction of everything inside the container. The analytical report should identify the technique, conditions, integration rules and any relevant exclusions before the number is used to make a broader comparison.
Bachem's technical FAQ distinguishes gross sample weight from net peptide content. Gross weight includes peptide material, counterions and associated water; net peptide content describes a different basis from chromatographic purity.[2] This distinction provides a concrete reason that a high purity result and a lower content result can coexist without being contradictory.
For example, imagine two reports that both display “99%” prominently. One might describe chromatographic area purity, while the other might report a quantitative assay on a specified basis. Unless the methods and reporting bases are reconciled, ranking the materials by the printed percentages is not a valid comparison. This is an illustrative reporting problem, not a finding about any commercial product.
Our separate article on the standard behind a milligram result explains why a numerical amount also needs a defined measurement basis. Neither a scale reading nor a purity label supplies all of that information on its own.
Keep suitability separate from a reassuring grade
A particularly clear example comes from FDA's 2024 reminder about ingredients for sterile compounding. The agency warned that food-grade ingredients are unsuitable for compounding sterile drugs without appropriate processing because of microbial and endotoxin contamination risks. It also described adverse reactions following injectable NAD+ products that were consistent with excessive endotoxins.[3]
That warning concerns a specific clinical-compounding context. It is not evidence that every NAD+ material has the same contamination, or that an ingredient's name explains the reactions. The transferable lesson is narrower: suitability for one use does not establish suitability for another, and a chemical-quality claim does not answer every microbiological question.
For laboratory work, define the actual need first. A screening experiment, a quantitative reference material and a stability investigation can require different documentation. Request the relevant attributes instead of assuming that the most impressive grade word is necessarily the best fit. Research materials must not be treated as ready-to-administer medicines because of an analytical percentage.
Build a batch-specific review record
A concise purchasing record can contain the supplier and catalog identifier, exact chemical form, lot number, specification version, certificate date, test methods and results. Add the intended laboratory application and any unresolved attributes. This creates an explanation for acceptance or rejection that another person can follow later.
Match the certificate to the supplied lot and verify its origin when necessary. A genuine document can still cover a different sample, an older specification or a narrower set of tests than the buyer assumed. The article on verifying a certificate with its issuing laboratory addresses that separate document-control step.
Treat missing information as missing information. Do not convert “not included in this report” into either “failed” or “passed.” Ask for clarification, decide whether an additional examination is needed, and record the limit of the conclusion. This approach is more useful than trying to assign every supplier to a universal hierarchy of marketing grades.
The sources below include FDA educational material, a dated FDA compounding alert, a manufacturer's technical FAQ and a clearly identified historical draft guidance. They explain the distinctions; no batch has been independently certified in this article.